Our recent work that identified the role of FTO in promoting tumor glycolysis and restricting T-cell responses, and developed the novel FTO inhibitor Dac51 which can increase CD8+ T-cell infiltration in tumors as part of the host adaptive immune response [38]. This evidence concerns the gene CD8A and neoplasm.